791OUpdated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. (23rd October 2018) - Fizazi, K; Carmel, A; Joly, F; Delva, R; Gravis, G; Rolland, F; Priou, F; Ferrero, J-M; Houede, N; Mourey, L; Theodore, C; Krakowski, I; et al.